NCT01025297View on ClinicalTrials.gov

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

December 31, 2012

Study Completion Date

March 31, 2013

Conditions
Hepatitis C
Interventions
DRUG

Interleukin-7

3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week

Trial Locations (8)

Unknown

Hopital Jean Verdier, Bondy

Beaujon Hospital, Clichy

Hopital Kremlin Bicêtre, Le Kremlin-Bicêtre

Hopital Civil, Strasbourg

Azienda Ospedaliero-Universitaria, Policlinico Sant'Orsola Malpighi, Bologna

Fatebenefratelli e Oftalmico, Milan

San Raffaele Scientific Institute, Milan

University of Zurich, Zurich

Sponsors

Lead Sponsor

Cytheris SA
All Listed Sponsors
lead

Cytheris SA

INDUSTRY

NCT01025297 - Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone | Biotech Hunter | Biotech Hunter